{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-300535","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2022-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.575050+00:00","generated_at":"2026-06-21T07:15:52.558973+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Corcept settles patent litigation with Hikma; generic Korlym entry set for October 2034","bullets":["Settlement with Hikma resolves patent litigation over generic Korlym in District of New Jersey.","Hikma granted right to sell generic Korlym in U.S. beginning October 1, 2034 or earlier under customary conditions.","Similar patent litigation against Teva Pharmaceuticals USA remains pending.","Settlement subject to court consent judgment and FTC/DOJ review.","CEO Belanoff noted the settlement allows focus on growing Korlym and developing cortisol modulator pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-300535","json":"https://secwatch.observer/filing/0001193125-22-300535.json","markdown":"https://secwatch.observer/filing/0001193125-22-300535.md","text":"https://secwatch.observer/filing/0001193125-22-300535.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000119312522300535/0001193125-22-300535-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000119312522300535/d430330d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T07:15:52.558973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}